Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.34)
# 417
Out of 4,479 analysts
141
Total ratings
39.85%
Success rate
29.51%
Average return
Main Sectors:
Top Industries:
37 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SKYE Skye Bioscience | Reiterates: Overweight | $14 | $8.16 | +71.67% | 4 | Jul 1, 2024 | |
| ETNB 89bio | Reiterates: Overweight | $29 | $7.44 | +289.78% | 11 | Jul 1, 2024 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $52 → $62 | $30.82 | +101.17% | 11 | Jul 1, 2024 | |
| SRPT Sarepta Therapeutics | Reiterates: Neutral | $128 | $156.07 | -17.99% | 10 | Jun 21, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.23 | +213.90% | 13 | Jun 20, 2024 | |
| CLDX Celldex Therapeutics | Reiterates: Overweight | $67 | $38.30 | +74.96% | 8 | Jun 18, 2024 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $115 | $39.97 | +187.75% | 9 | Jun 12, 2024 | |
| MREO Mereo BioPharma Group | Reiterates: Overweight | $7 | $3.65 | +92.04% | 6 | Jun 12, 2024 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $5 | $0.54 | +832.84% | 3 | May 31, 2024 | |
| CDXS Codexis | Initiates: Overweight | $11 | $2.91 | +278.01% | 1 | May 30, 2024 | |
| IRON Disc Medicine | Reiterates: Overweight | $85 | $45.64 | +86.24% | 5 | May 28, 2024 | |
| FULC Fulcrum Therapeutics | Initiates: Overweight | $23 | $6.25 | +268.00% | 1 | May 20, 2024 | |
| ABEO Abeona Therapeutics | Maintains: Overweight | $28 → $21 | $4.14 | +407.25% | 6 | May 16, 2024 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $8 | $4.77 | +67.71% | 2 | May 14, 2024 | |
| ADMA ADMA Biologics | Maintains: Overweight | $8 → $10 | $11.39 | -12.17% | 5 | May 10, 2024 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $21 | $7.14 | +194.32% | 3 | Apr 30, 2024 | |
| HUMA Humacyte | Reiterates: Overweight | $7 | $5.32 | +31.58% | 5 | Apr 1, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $2 → $3 | $8.29 | -63.81% | 2 | Mar 6, 2024 | |
| FOLD Amicus Therapeutics | Reiterates: Overweight | $22 | $9.78 | +125.06% | 4 | Feb 29, 2024 | |
| LCTX Lineage Cell Therapeutics | Reiterates: Overweight | $6 | $0.95 | +530.91% | 3 | Feb 5, 2024 | |
| QURE uniQure | Reiterates: Overweight | $21 | $4.22 | +397.63% | 2 | Dec 20, 2023 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $19 → $35 | $41.64 | -15.95% | 3 | Sep 26, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | $90 → $20 | $7.28 | +174.73% | 2 | Aug 30, 2023 | |
| DRTS Alpha Tau Medical | Reiterates: Overweight | $23 | $2.47 | +831.17% | 2 | Aug 29, 2023 | |
| MBIO Mustang Bio | Reiterates: Overweight | $18 | $0.59 | +2,927.75% | 1 | Aug 24, 2023 | |
| OCUP Ocuphire Pharma | Reiterates: Overweight | $17 | $1.58 | +975.95% | 3 | Aug 14, 2023 | |
| DRRX DURECT | Maintains: Overweight | $44 → $41 | $1.35 | +2,937.04% | 2 | Aug 10, 2023 | |
| GLTO Galecto | Initiates: Overweight | $16 | $0.47 | +3,307.16% | 1 | Mar 17, 2023 | |
| IBIO iBio, Inc. | Downgrades: Neutral | $1,250 → $85 | $1.93 | +4,315.58% | 3 | Oct 7, 2022 | |
| HEPA Hepion Pharmaceuticals | Initiates: Overweight | $70 | $1.10 | +6,263.64% | 1 | Feb 28, 2022 | |
| EVLO Evelo Biosciences | Initiates: Overweight | n/a | $0.04 | - | 1 | Jun 23, 2021 | |
| CMMB Chemomab Therapeutics | Initiates: Overweight | n/a | $0.95 | - | 1 | May 26, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | n/a | $1.69 | - | 3 | May 7, 2021 | |
| MRKR Marker Therapeutics | Initiates: Overweight | n/a | $5.35 | - | 1 | Mar 19, 2021 | |
| EVGN Evogene | Initiates: Overweight | n/a | $0.64 | - | 1 | Dec 1, 2020 | |
| GLMD Galmed Pharmaceuticals | Assumes: Overweight | n/a | $0.30 | - | 1 | Jan 30, 2020 | |
| PHGE BiomX | Initiates: Overweight | n/a | $0.36 | - | 1 | Jan 9, 2020 |
Skye Bioscience
Jul 1, 2024
Reiterates: Overweight
Price Target: $14
Current: $8.16
Upside: +71.67%
89bio
Jul 1, 2024
Reiterates: Overweight
Price Target: $29
Current: $7.44
Upside: +289.78%
PTC Therapeutics
Jul 1, 2024
Maintains: Overweight
Price Target: $52 → $62
Current: $30.82
Upside: +101.17%
Sarepta Therapeutics
Jun 21, 2024
Reiterates: Neutral
Price Target: $128
Current: $156.07
Upside: -17.99%
Taysha Gene Therapies
Jun 20, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.23
Upside: +213.90%
Celldex Therapeutics
Jun 18, 2024
Reiterates: Overweight
Price Target: $67
Current: $38.30
Upside: +74.96%
Ultragenyx Pharmaceutical
Jun 12, 2024
Reiterates: Overweight
Price Target: $115
Current: $39.97
Upside: +187.75%
Mereo BioPharma Group
Jun 12, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.65
Upside: +92.04%
X4 Pharmaceuticals
May 31, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.54
Upside: +832.84%
Codexis
May 30, 2024
Initiates: Overweight
Price Target: $11
Current: $2.91
Upside: +278.01%
Disc Medicine
May 28, 2024
Reiterates: Overweight
Price Target: $85
Current: $45.64
Upside: +86.24%
Fulcrum Therapeutics
May 20, 2024
Initiates: Overweight
Price Target: $23
Current: $6.25
Upside: +268.00%
Abeona Therapeutics
May 16, 2024
Maintains: Overweight
Price Target: $28 → $21
Current: $4.14
Upside: +407.25%
Capricor Therapeutics
May 14, 2024
Reiterates: Overweight
Price Target: $8
Current: $4.77
Upside: +67.71%
ADMA Biologics
May 10, 2024
Maintains: Overweight
Price Target: $8 → $10
Current: $11.39
Upside: -12.17%
Actinium Pharmaceuticals
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $7.14
Upside: +194.32%
Humacyte
Apr 1, 2024
Reiterates: Overweight
Price Target: $7
Current: $5.32
Upside: +31.58%
Rigel Pharmaceuticals
Mar 6, 2024
Maintains: Neutral
Price Target: $2 → $3
Current: $8.29
Upside: -63.81%
Amicus Therapeutics
Feb 29, 2024
Reiterates: Overweight
Price Target: $22
Current: $9.78
Upside: +125.06%
Lineage Cell Therapeutics
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.95
Upside: +530.91%
uniQure
Dec 20, 2023
Reiterates: Overweight
Price Target: $21
Current: $4.22
Upside: +397.63%
Soleno Therapeutics
Sep 26, 2023
Maintains: Overweight
Price Target: $19 → $35
Current: $41.64
Upside: -15.95%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $7.28
Upside: +174.73%
Alpha Tau Medical
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.47
Upside: +831.17%
Mustang Bio
Aug 24, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.59
Upside: +2,927.75%
Ocuphire Pharma
Aug 14, 2023
Reiterates: Overweight
Price Target: $17
Current: $1.58
Upside: +975.95%
DURECT
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $1.35
Upside: +2,937.04%
Galecto
Mar 17, 2023
Initiates: Overweight
Price Target: $16
Current: $0.47
Upside: +3,307.16%
iBio, Inc.
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.93
Upside: +4,315.58%
Hepion Pharmaceuticals
Feb 28, 2022
Initiates: Overweight
Price Target: $70
Current: $1.10
Upside: +6,263.64%
Evelo Biosciences
Jun 23, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.04
Upside: -
Chemomab Therapeutics
May 26, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.95
Upside: -
Ocugen
May 7, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.69
Upside: -
Marker Therapeutics
Mar 19, 2021
Initiates: Overweight
Price Target: n/a
Current: $5.35
Upside: -
Evogene
Dec 1, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.64
Upside: -
Galmed Pharmaceuticals
Jan 30, 2020
Assumes: Overweight
Price Target: n/a
Current: $0.30
Upside: -
BiomX
Jan 9, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.36
Upside: -